Ara
Toplam kayıt 1, listelenen: 1-1
Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells
(Spandidos Publications, 2013)
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approved for the treatment of patients with relapsed and refractory multiple myeloma. A number of studies have been conducted to ...